

REMARKS

Upon entry of the foregoing amendments, Claims 1-34 are pending in the application. Applicants have added new Claims 26-34. The amendments to the claims add no new matter and are fully supported by the specification and claims as originally filed. Support for new Claims 26-34 can be found, for example, in paragraphs [0023]-[0030], and elsewhere throughout the specification.

In response to the Restriction Requirement, Applicants hereby elect to prosecute claims directed to Group II: methods for treating a cardiovascular disease comprising administration of an AA₁RA and a beta blocker. Applicants also elect heart failure as a species of cardiovascular disease, KW-3902 as a species of AA₁RA, and carvedilol as a species of beta blocker. Claims that read on this species include Claims 10-13, and new Claims 26-34. Pursuant to M.P.E.P. §809.02(a), Applicants understand that upon a finding that the generic claim is allowable, Applicants will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of the generic claims.

CONCLUSION


The undersigned has made a good faith effort to respond to the Restriction Requirement. Nevertheless, if any undeveloped issues remain or if any issue require clarification, the Examiner is invited to call the undersigned attorney to resolve such issues promptly.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 11-21-07

By: 
Ned A. Israelsen
Registration No. 29,655
Attorney of Record
Customer No. 20,995
(619) 235-8550